Results of the ARBITER 6–HALTS trial indicate a superiority of the lipid-modifying agent nicotinic acid over ezetimibe for the treatment of atherosclerotic lesions. These findings could have substantial implications for patients worldwide who remain at moderate to high risk of cardiovascular complications because of low levels of HDL cholesterol. But is the evidence substantiated?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Taylor, A. J. et al. Extended-release nicotinic acid or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361, 2113–2122 (2009).
Rossi, A. et al. The renin-angiotensin-aldosterone system and carotid artery disease in mild-to-moderate primary hypertension. J. Hypertens. 18, 1401–1409 (2000).
Mancia, G. et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25, 1105–1187 (2007).
Graham, I. et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 14, (Suppl. 2) S1–S113 (2007).
Smith, S. C. Jr et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113, 2363–2372 (2006).
Bays, H. E. et al. Blood pressure-lowering effects of extended-release nicotinic acid alone and extended-release nicotinic acid/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin. Ther. 31, 115–122 (2009).
Nissen, S. E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304–1316 (2007).
Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
Forrest, M. J. et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154, 1465–1473 (2008).
Wang, J. G. et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 37, 1933–1940 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Rossi, G., Rizzoni, D. Raising HDL cholesterol levels: a flight of Icarus?. Nat Rev Endocrinol 6, 245–246 (2010). https://doi.org/10.1038/nrendo.2010.44
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.44
